Capmatinib is approved for metastatic non-small cell lung cancer

Share This Post

August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Administration gave capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) regular approval.

Based on the initial overall response rate and duration of response in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multi-cohort research, capmatinib was previously given accelerated approval for the same indication on May 6, 2020. Based on data from an additional 63 patients and an additional 22 months of follow-up to evaluate response durability and confirm therapeutic benefit, the conversion to regular approval was made.

160 patients with advanced NSCLC with a mutation skipping exon 14 of MET showed efficacy. Patients received capmatinib 400 mg twice day until their disease progressed or the side effects became intolerable.

A Blinded Independent Review Committee determined the ORR and duration of response (DOR) as the major efficacy measures (BIRC). 60 individuals who had never received treatment had an ORR of 68% (95% CI: 55, 80) and a DOR of 16.6 months (95% CI: 8.4, 22.1). The ORR was 44% (95% CI: 34, 54) among 100 patients who had previously received treatment, and the DOR was 9.7 months (95% CI: 5.6, 13).

The patients’ average age was 71 years (48 to 90). The following specific demographics were reported: 61% female, 77% White, 61% never smoked, 83% had adenocarcinoma, and 16% had metastases to the central nervous system. 81% of patients who had previously had treatment had only gotten one line of systemic therapy; 16% had received two; and 3% had received three. 86% of patients who had previously had treatment had platinum-based chemotherapy.

Patients experienced edoema, nausea, musculoskeletal pain, weariness, vomiting, dyspnea, coughing, and decreased appetite the most frequently (20%).

Capmatinib should be taken orally twice daily at a dose of 400 mg, with or without meals.

View full prescribing information for Tabrecta

 

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟